ASH Stock Recent News

WILMINGTON, Del., April 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its second-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Wednesday, April 30, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 10 a.m. ET on Thursday, May 1. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com.

ASH is investing in modernizing equipment for microbial protection in personal care applications at its Technical Center in Sao Paulo.

Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China

WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person.

ASH closes the sales of its Avoca business, the last entity remaining from the Pharmachem acquisition.

Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed.

Ashland is generating attractive free cash flow and is well-positioned to achieve its 2027 target of $600 million EBITDA and 50% FCF conversion rate. Despite the stock selling off over the last 8 months, Ashland's strategic acquisitions and divestitures have strengthened its market position, with a focus on high-margin, patent-protected products. Ashland's strong balance sheet, low leverage, and fixed-rate debt provide stability and flexibility to navigate the current downcycle in the specialty chemicals sector.

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are strong, with $133.1 million in cash and equivalents, funding operations into Q4 2026, despite high clinical development costs. The market undervalues TCRX stock, trading at less than half its Q3 assets, presenting an opportunity amid current biotech pessimism.

Organic sales volume growth in ASH's Personal Care, Specialty Additives and Intermediates segments largely offset lower volumes in Life Sciences in Q1.

Ashland Inc. (NYSE:ASH ) Q1 2025 Earnings Conference Call January 29, 2025 9:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo Chris Parkinson - Wolfe Research John Roberts - Mizuho David Begleiter - Deutsche Bank Jeff Zekauskas - JPMorgan Mike Harrison - Seaport Research Partners Bhavesh Lodaya - BMO Capital Markets Josh Spector - UBS Operator Good day and thank you for standing by. Welcome to the Ashland Inc. First Quarter 2025 Earnings Conference Call.